수의료용 모노클로널 항체 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Monoclonal Antibodies In Veterinary Health Market size is expected to reach USD 9.93 Billion in 2034 from USD 1.99 Billion (2025) growing at a CAGR of 19.59% during 2026-2034.

The Global Monoclonal Antibodies in Veterinary Health Market is experiencing robust growth driven by rising pet ownership and increasing demand for advanced animal healthcare solutions. Monoclonal antibodies are gaining popularity for treating chronic conditions such as osteoarthritis and dermatological disorders in companion animals. Growing awareness among pet owners regarding specialized veterinary treatments is contributing significantly to market expansion.

Key drivers include technological advancements in biotechnology, increasing livestock disease prevalence, and a stronger focus on animal welfare. Pharmaceutical companies are investing heavily in research and development to create targeted biologics with improved safety profiles. Additionally, regulatory approvals for veterinary monoclonal antibody therapies are accelerating commercialization and expanding product portfolios across key regions.

In the coming years, innovation in antibody engineering and cost-effective manufacturing processes will strengthen market penetration. Emerging markets present significant untapped potential due to expanding veterinary healthcare infrastructure. As precision medicine gains momentum in animal health, monoclonal antibodies are expected to play a transformative role in improving treatment outcomes and supporting sustainable livestock production globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Dermatology
• Pain
• Others

By Animal Type

• Dogs
• Others

By End User

• Veterinary Hospitals
• Others

COMPANIES PROFILED

• Zoetis, Merck Co Inc, Elanco, Boehringer Ingelheim GmbH, Indian Immunologicals Ltd, Virbac
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH MARKET: BY ANIMAL TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Animal Type
• 5.2. Dogs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Veterinary Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Application
  • 7.2.2 By Animal Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Application
  • 7.3.2 By Animal Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Application
  • 7.4.2 By Animal Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Application
  • 7.5.2 By Animal Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Application
  • 7.6.2 By Animal Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MONOCLONAL ANTIBODIES IN VETERINARY HEALTH INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Zoetis
  • 9.2.2 Merck & Co Inc
  • 9.2.3 Elanco
  • 9.2.4 Boehringer Ingelheim GmbH
  • 9.2.5 Indian Immunologicals Ltd
  • 9.2.6 Virbac